Hjem
Jan Didrik Schjøtts bilde

Jan Didrik Schjøtt

Professor
  • E-postJan.Schjott@uib.no
  • Telefon+47 55 97 30 93+47 404 63 363
  • Besøksadresse
    Haukeland universitetssykehus, Laboratoriebygget
    5009 Bergen
  • Postadresse
    Postboks 7804
    5020 Bergen
Vitenskapelig artikkel
  • Vis forfatter(e) (2022). Serum or Plasma for Quantification of Direct Oral Anticoagulants? Therapeutic Drug Monitoring. 578-584.
  • Vis forfatter(e) (2022). Perceptions of generic medicines and medication adherence after percutaneous coronary intervention: a prospective multicentre cohort study. BMJ Open. 13 sider.
  • Vis forfatter(e) (2022). Nurses as adverse drug reaction reporting advocates. European Journal of Cardiovascular Nursing. 4 sider.
  • Vis forfatter(e) (2022). Identifying target areas of medicines information efforts to pregnant and breastfeeding women by reviewing questions to SafeMotherMedicine: A Norwegian web-based public medicines information service. BMC Pregnancy and Childbirth.
  • Vis forfatter(e) (2022). A liposomal formulation of simvastatin and doxorubicin for improved cardioprotective and anti-cancer effect. International Journal of Pharmaceutics.
  • Vis forfatter(e) (2022). A Patient With Sepsis-Induced Multiorgan Failure and Increasing Serum Methadone Concentration: A Case Study. Therapeutic Drug Monitoring. 366-368.
  • Vis forfatter(e) (2021). Ultrasound and Microbubbles Enhance Uptake of Doxorubicin in Murine Kidneys. Pharmaceutics.
  • Vis forfatter(e) (2021). Review of Clinical Questions Submitted to Norwegian Drug Information Centres Concerning Administration and Dosage to Older Patients of Relevance to Patient-Central Care. Pharmaceutics.
  • Vis forfatter(e) (2021). Quetiapine, Misuse and dependency: A case-series of questions to a Norwegian network of drug information centers. Drug, Healthcare and Patient Safety. 151-157.
  • Vis forfatter(e) (2020). Ultrasound‐ and microbubble‐assisted gemcitabine delivery to pancreatic cancer cells. Pharmaceutics. 1-15.
  • Vis forfatter(e) (2020). Rethinking rehabilitation after percutaneous coronary intervention: a protocol of a multicentre cohort study on continuity of care, health literacy, adherence and costs at all care levels (the CONCARDPCI). BMJ Open. e031995.
  • Vis forfatter(e) (2020). Perception of prescribing factors and purchase statistics of non-steroidal anti-inflammatory drugs in an orthopedic clinic. BMC Research Notes. 1-6.
  • Vis forfatter(e) (2020). Intracellular cytidine deaminase regulates gemcitabine metabolism in pancreatic cancer cell lines. Drug Metabolism And Disposition. 153-158.
  • Vis forfatter(e) (2019). Analysis of consensus among drug interaction databases with regard to combinations of psychotropics. Basic & Clinical Pharmacology & Toxicology. 1-7.
  • Vis forfatter(e) (2019). A retrospective comparison of inappropriate prescribing of psychotropics in three Norwegian nursing homes in 2000 and 2016 with prescribing quality indicators. BMC Medical Informatics and Decision Making. 1-11.
  • Vis forfatter(e) (2018). Use of references in responses from Scandinavian drug information centres. Medicines.
  • Vis forfatter(e) (2018). The possibility of therapeutic drug monitoring of the most important interactions in nursing homes. Current Clinical Pharmacology.
  • Vis forfatter(e) (2018). Rituximab serum concentrations and anti-rituximab antibodies during B-cell depletion therapy for myalgic encephalopathy/chronic fatigue syndrome. Clinical Therapeutics. 9.
  • Vis forfatter(e) (2018). Challenges adhering to a medication regimen following first-time percutaneous coronary intervention: A patient perspective. International Journal of Nursing Studies. 16-24.
  • Vis forfatter(e) (2018). Analysis of questions about use of drugs in breastfeeding to Norwegian drug information centres . International Breastfeeding Journal. 1-9.
  • Vis forfatter(e) (2017). Quality assessment of structure and language elements of written responses given by seven Scandinavian drug information centres. European Journal of Clinical Pharmacology. 623-631.
  • Vis forfatter(e) (2016). Relationship Between Time Consumption and Quality of Responses to Drug-Related Queries:A Study From Seven Drug Information Centers in Scandinavia. Clinical Therapeutics. 1738-1749.
  • Vis forfatter(e) (2016). Physicians' Perception of Teratogenic Risk and Confidence in Prescribing Drugs in Pregnancy - Influence of Norwegian Drug Information Centers. Clinical Therapeutics. 1102-1108.
  • Vis forfatter(e) (2016). Drug information services today: current role and future perspectives in rational drug therapy. Clinical Therapeutics. 414-421.
  • Vis forfatter(e) (2016). Antipsychotic drugs and risk of hip fracture among people older than 60 years in Norway. Journal of The American Geriatrics Society. 1203-1209.
  • Vis forfatter(e) (2016). A human clinical trial using ultrasound and microbubbles to enhance gemcitabine treatment of inoperable pancreatic cancer. Journal of Controlled Release. 172-181.
  • Vis forfatter(e) (2015). Preanalytical stability of gemcitabine and its metabolite 2', 2'-difluoro-2'-deoxyuridine in whole blood-assessed by liquid chromatography tandem mass spectrometry. Journal of Pharmaceutical Sciences. 4427-4432.
  • Vis forfatter(e) (2015). Liquid chromatography/tandem mass spectrometry method for simultaneous quantification of eight endogenous nucleotides and the intracellular gemcitabine metabolite dFdCTP in human peripheral blood mononuclear cells. Journal of chromatography. B. 212-220.
  • Vis forfatter(e) (2015). Cross-reactivity of the CEDIA buprenorphine assay in drugs-of-abuse screening: influence of dose and metabolites of opioids. Substance Abuse and Rehabilitation. 131-139.
  • Vis forfatter(e) (2014). Questions about complementary and alternative medicine to the Regional Medicines Information and Pharmacovigilance Centres in Norway (RELIS): a descriptive pilot study. BMC Complementary and Alternative Medicine.
  • Vis forfatter(e) (2014). Myocardial injury in a 41-year-old male treated with metylphenidate: a case report. BMC Research Notes.
  • Vis forfatter(e) (2014). Morphine enhances doxorubicin-induced cardiotoxicity in the rat. Cardiovascular Toxicology. 251-259.
  • Vis forfatter(e) (2014). Joint medicine-information and pharmacovigilance services could improve detection and communication about drug-safety problems. Drug, Healthcare and Patient Safety. 89-92.
  • Vis forfatter(e) (2014). Factors associated with time consumption when answering drug-related queries to Scandinavian drug information centres: a multi-centre study. European Journal of Clinical Pharmacology. 1395-1401.
  • Vis forfatter(e) (2014). Diazoxide protects against doxorubicin-induced cardiotoxicity in the rat. BMC Pharmacology & Toxicology. 8 sider.
  • Vis forfatter(e) (2013). Teratogenic risk perception and confidence in use of medicines in pairs of pregnant women and general practitioners based on patient information leaflets. Drug Safety. 481-489.
  • Vis forfatter(e) (2013). A short-time model to study relevant indices of cardiotoxicity of doxorubicin in the rat. Toxicology Mechanisms and Methods. 412-418.
  • Vis forfatter(e) (2012). Risk perception and medicines information needs in pregnant women with epilepsy - A qualitative study. Seizure. 597-602.
  • Vis forfatter(e) (2012). En retrospektiv analyse av tannlegehenvendelser til regionale legemiddelinformasjonssentre (RELIS). Den norske tannlegeforenings tidende. 284-288.
  • Vis forfatter(e) (2012). A question–answer pair (QAP) database integrated with websites to answer complex questions submitted to the Regional Medicines Information and Pharmacovigilance Centres in Norway (RELIS): a descriptive study. BMJ Open. 6 sider.
  • Vis forfatter(e) (2012). A Blended Learning Course Design in Clinical Pharmacology for Post-graduate Dental Students. Open Dentistry Journal. 182-187.
  • Vis forfatter(e) (2011). Prevention of urinary tract infections in nursing homes: lack of evidence-based prescription? BMC Geriatrics. 6 sider.
  • Vis forfatter(e) (2011). Hvordan er kvaliteten på omtalen av interaksjoner i Felleskatalogen? Norsk Farmaceutisk Tidsskrift. 20-24.
  • Vis forfatter(e) (2011). Clinical characteristics of patients with drug hypersensitivity in Norway: a single-centre study. Pharmacoepidemiology and Drug Safety. 506-513.
  • Vis forfatter(e) (2010). Which factors predict the time spent answering queries to a drug information centre? Pharmacy World & Science (PWS). 799-804.
  • Vis forfatter(e) (2010). How are antibacterials used in nursing homes? Results from a point-prevalence prescription study in 44 Norwegian nursing homes. Pharmacoepidemiology and Drug Safety. 1025-1030.
  • Vis forfatter(e) (2009). Hepatitis Caused by Lotus-f3? Basic & Clinical Pharmacology & Toxicology. 414-416.
  • Vis forfatter(e) (2009). Drug use in pregnancy-physicians' evaluation of quality and clinical impact of drug information centres. European Journal of Clinical Pharmacology. 303-308.
  • Vis forfatter(e) (2008). Advice on drug safety in pregnancy - Are there differences between commonly used sources of information? Drug Safety. 799-806.
  • Vis forfatter(e) (2006). Pretreatment with tamoxifen does not change acute epirubicin cardiotoxicity in rats. Basic & Clinical Pharmacology & Toxicology. 231-234.
  • Vis forfatter(e) (2003). Tamoxifen administration and metabolism in nude mice and nude rats. Journal of Steroid Biochemistry and Molecular Biology. 361-367.
  • Vis forfatter(e) (2003). Bruk av sovemidler på alders- og sykehjem i Hordaland og Sogn og Fjordane. Tidsskrift for Den norske legeforening. 1068-1069.
  • Vis forfatter(e) (2002). Quality and impact of problem-oriented drug information: a method to change clinical practice among physicians? European Journal of Clinical Pharmacology. 897-902.
  • Vis forfatter(e) (2002). Egenvurdering av arbeidsmiljø, og erfaringer med jobbtilpasning blant bussjåfører. Tidsskrift for Den norske legeforening. 797-800.
  • Vis forfatter(e) (2001). Polypharmacy among patients admitted to hospital with rheumatic diseases. Pharmacy World & Science (PWS). 153-158.
  • Vis forfatter(e) (2001). Polypharmacy among patients admitted to hospital with rheumatic diseases. Pharmacy World & Science (PWS). 153-158.
  • Vis forfatter(e) (2001). Assessing the effects of an intervention by a pharmacist on prescribing and administration of hypnotics in nursing homes. Pharmacy World & Science (PWS). 227-231.
  • Vis forfatter(e) (2000). Protective effects of repetitive injections of radiographic contrast media on the subsequent tolerance to ischemia in the isolated rat heart. Cardiovascular and Interventional Radiology. 433-471.
  • Vis forfatter(e) (2000). Hyperosmotic perfusion of the beating rat heart and the role of the Na+/K+/2Cl- co-transporter and the Na+/H+ exchanger. Basic Research in Cardiology. 19-27.
  • Vis forfatter(e) (2000). Hva spør helsepersonell RELIS VEST om og hvor fornøyde er de med svarene? Tidsskrift for Den norske legeforening. 204-207.
  • Vis forfatter(e) (1999). Hyperosmotic pre-treatment reduces infarct size in the rat heart. Physiological Research. 331-340.
  • Vis forfatter(e) (1999). A survey of hypnotic use in geriatric institutions in Sogn og Fjordane, Norway. Aging Clinical and Experimental Research. 50-55.
  • Vis forfatter(e) (1998). Use of hypnotics among patients in geriatric institutions. International Journal of Geriatric Psychiatry. 846-851.
  • Vis forfatter(e) (1997). Manganese and the heart: acute cardiodepression and myocardial accumulation of manganese. Acta Physiologica Scandinavica. 33-40.
  • Vis forfatter(e) (1997). Effects of MnDPDP, DPDP--, and MnCl2 on cardiac energy metabolism and manganese accumulation. An experimental study in the isolated perfused rat heart. Investigative Radiology. 205-211.
  • Vis forfatter(e) (1996). Protection induced by a brief ischemic episode in the Langendorff perfused rat heart. Academic Radiology. 645-650.
  • Vis forfatter(e) (1996). Pretreatment with ischaemia attenuates acute epirubicin-induced cardiotoxicity in isolated rat hearts. Pharmacology and Toxicology. 381-386.
  • Vis forfatter(e) (1996). Effects of eicosapentaenoic acid and docosahexaenoic acid diet supplement on tolerance to the cardiotoxicity of epirubicin and to ischaemia reperfusion in the isolated rat heart. Pharmacology and Toxicology. 65-72.
  • Vis forfatter(e) (1995). Preconditioning by brief ischemic episodes in the isolated rat heart assessed by 31P NMR spectroscopy: dissociation between metabolic and functional recovery? Scandinavian Journal of Clinical and Laboratory Investigation. 67-78.
  • Vis forfatter(e) (1995). Effects of MnDPDP, DPDP-- and MnCl2 upon cardiac function: an experimental study in the Langendorff perfused rat heart. Investigative Radiology. 159-167.
  • Vis forfatter(e) (1995). Contractile responses to electrolyte changes during coronary bolus perfusion: a comparative study in isolated rat, guinea pig and rabbit hearts. Investigative Radiology. 173-180.
  • Vis forfatter(e) (1994). Lidocaine interactions with exogenous and endogenous adenosine in the isolated rat heart. Pharmacology and Toxicology. 212-217.
  • Vis forfatter(e) (1994). Ischemic episodes less than five min produce preconditioning but not stunning in the isolated rat heart. Acta Physiologica Scandinavica. 281-291.
  • Vis forfatter(e) (1994). Early detection of regional myocardial ischemia in ex vivo piglet hearts: MR imaging with magnetization transfer. Journal of Magnetic Resonance Imaging. 603-608.
  • Vis forfatter(e) (1993). Infusion of EPA and DHA lipid emulsions: effects on heart lipids and tolerance to ischaemia-reperfusion in the isolated rat heart. Scandinavian Journal of Clinical and Laboratory Investigation. 31-39.
  • Vis forfatter(e) (1993). Effect of GD-DTPA-BMA on magnetization transfer: Application to rapid imaging of cardiac ischemia. Journal of Magnetic Resonance Imaging. 31-39.
Faglig foredrag
  • Vis forfatter(e) (2019). Sonoporation and gemcitabine delivery in pancreatic cancer cell lines.
  • Vis forfatter(e) (2015). The Drug Information Center in 2015 – still a valid concept?
  • Vis forfatter(e) (2010). Antidepressiva og interaksjoner.
Vitenskapelig foredrag
  • Vis forfatter(e) (2022). Informing patients about potential adverse drug reactions after percutaneous coronary intervention reduces the occurrence of self-reported adverse drug reactions.
  • Vis forfatter(e) (2018). Discontinuation of drug treatment due to side effects after first-time percutaneous coronary intervention: a patient perspective.
  • Vis forfatter(e) (2013). Risk perception among health care professionals and the public: Experience from regional medicines and pharmacovigilance centres (RELIS) in Norway.
  • Vis forfatter(e) (2013). Cedia Assays For Buprenorphine, Methadone, And Eddp In Urine – Simple Methods, But Sufficient For The Purpose?
  • Vis forfatter(e) (2011). Risk perception and drug information needs for pregnant women with epilepsy – a qualitative study.
  • Vis forfatter(e) (2011). A question-answer pair (QAP) database integrated with websites for the regional medicines information and pharmacovigilance centres in Norway (RELIS).
Leder
  • Vis forfatter(e) (2009). Legemiddelhåndtering hos barn og eldre. Tidsskrift for Den norske legeforening. 1731-1731.
Leserinnlegg
  • Vis forfatter(e) (2020). Ny bivirkningsforskrift gir undervisningsbehov. Tidsskrift for Den norske legeforening.
  • Vis forfatter(e) (2018). Ciprofloxacin and acute aortic valve damage. Medical Hypotheses. 35-35.
  • Vis forfatter(e) (2014). Re: Glem ikke Marevanen! Tidsskrift for Den norske legeforening. 2125-2125.
  • Vis forfatter(e) (2009). Warnings against candesartan in pregnancy are not implemented in physicians' practice. European Journal of Obstetrics, Gynecology, and Reproductive Biology. 235-235.
Short communication
  • Vis forfatter(e) (2021). Acute Myocardial Injury in a Patient with Attention Deficit Hyperactivity Disorder and History of Substance Abuse: A Multimodality Imaging Point of View. Journal of Cardiovascular Development and Disease (JCDD).
  • Vis forfatter(e) (2019). Short communication: Distribution of psychotropic drugs into lipoproteins. Therapeutic Drug Monitoring. 766-771.
  • Vis forfatter(e) (2017). Shortage of digitoxin and switching to digoxin in Norway: A retrospective study of blood samples submitted to a clinical pharmacology laboratory. Basic & Clinical Pharmacology & Toxicology. 74-77.
  • Vis forfatter(e) (2017). Risk perception regarding drug use in pregnancy. American Journal of Obstetrics and Gynecology. 375-378.
  • Vis forfatter(e) (2017). Physicians' questions concerning drug use among older patients: experience from Norwegian drug information centres (RELIS) in the period 2010-2015. Aging Clinical and Experimental Research. 1-4.
  • Vis forfatter(e) (2016). Legemiddelbruk hos blodgivere. Tidsskrift for Den norske legeforening. 718-720.
  • Vis forfatter(e) (2016). Challenges in psychopharmacology: a drug information centre perspective. Journal of Clinical Pharmacy and Therapeutics. 4-6.
  • Vis forfatter(e) (2014). En mann i 70-årene med infeksjon og alvorlig syre-base-forstyrrelse. Tidsskrift for Den norske legeforening. 315-319.
  • Vis forfatter(e) (2013). Medikamentell behandling av nevropatiske smerter. Tidsskrift for Den norske legeforening. 971-973.
  • Vis forfatter(e) (2009). Ulike doseringsanbefalinger for jern. Norsk Farmaceutisk Tidsskrift. 21-21.
Vitenskapelig antologi/Konferanseserie
  • Vis forfatter(e) (2011). Liver Biopsy in Modern Medicine. IntechOpen.
Mastergradsoppgave
  • Vis forfatter(e) (2018). A literature-based concept analysis in supply chain risk management for the Norwegian Atlantic salmon industry.
  • Vis forfatter(e) (2017). Val av antiflogistika ved Ortopedisk klinikk i Helse Bergen.
  • Vis forfatter(e) (2014). Legers risikopersepsjon ved bruk av legemidler i graviditeten. Endres denne ved informasjon og råd fra RELIS.
  • Vis forfatter(e) (2012). Using magnetic resonance imaging to assess the extent of infarction and salvageable myocardial tissue after pharmacological postconditioning in an experimental ex vivo model.
  • Vis forfatter(e) (2011). Analyse av psykofarmaka-Metodeutvikling for kromatografisk analyse av utvalgte antidepressiva og antipsykotika i serum.
  • Vis forfatter(e) (2009). Spontanrapportering av bivirkninger hos barn i Norge for perioden 1998-2007.
  • Vis forfatter(e) (2008). Information on drug interactions: A comparison of two common sources of drug information in Norway.
  • Vis forfatter(e) (2008). A rat model to assess interventions to reduce cardiotoxicity of anthracyclines. Does pretreatment with morphine reduce cardiotoxicity of doxorubicin?
Populærvitenskapelig artikkel
  • Vis forfatter(e) (2015). Inspirerende foredrag om antibiotikaresistens. Norsk Farmaceutisk Tidsskrift.
  • Vis forfatter(e) (2015). Folk dør av hemmelige bivirkninger. Bergens Tidende.
Kronikk
  • Vis forfatter(e) (2022). Fornyet vurdering – stoler du på legen? Tidsskrift for Den norske legeforening. 682-682.
Brev til redaktøren
  • Vis forfatter(e) (2022). The Possibility of Hypersensitivity Myocarditis following COVID-19 Vaccines: Implications for Contrast Echocardiography. Cardiology. 417-418.
  • Vis forfatter(e) (2022). Second Opinion in Pharmacotherapy of ADHD: Do Not Postpone It! Clinical Therapeutics. 924-925.
  • Vis forfatter(e) (2021). Ultrasound and microbubble assisted drug delivery – a clinical pharmacological perspective. Pharmacological Research.
  • Vis forfatter(e) (2019). Stability of antidepressants and antipsychotics in gel separator tubes. Therapeutic Drug Monitoring. 249-250.
  • Vis forfatter(e) (2019). Disproportionality analysis for identification of drug safety questions in a database shared by the Norwegian network of drug information centres (RELIS). European Journal of Clinical Pharmacology.
  • Vis forfatter(e) (2016). Benefits of a national network of drug information centres: RELIS. European Journal of Clinical Pharmacology. 125-126.
  • Vis forfatter(e) (2009). Legemidler ved pollenallergi, graviditet og amming. Tidsskrift for Den norske legeforening. 1354-1354.
Doktorgradsavhandling
  • Vis forfatter(e) (2020). Drug delivery in pancreatic cancer.
  • Vis forfatter(e) (2015). Cardiotoxicity of Doxorubicin. A Study of Methods and Protective Interventions in Rat Models.
  • Vis forfatter(e) (2013). Drug information in pregnancy - attitudes and needs among pregnant women and physicians.
  • Vis forfatter(e) (2012). E-learning: A study of students' attitudes and learning outcome when using blended learning with integration of multimedia instructions.
  • Vis forfatter(e) (1996). Myocardial protection : functional and metabolic characteristics of two endogeneous protective principles. 118.
Intervju
  • Vis forfatter(e) (2010). Håndtering av seponeringsreaksjoner.
Vitenskapelig Kapittel/Artikkel/Konferanseartikkel
  • Vis forfatter(e) (2011). Adverse Effects of Drugs and Toxins on the Liver. 27 sider.
  • Vis forfatter(e) (2010). Legemiddelinformasjon. 9 sider.
Sammendrag/abstract
  • Vis forfatter(e) (2021). Perceptions of efficacy and safety of generic medicines in patients after percutaneous coronary intervention. European Heart Journal.
  • Vis forfatter(e) (2021). Communication of Potential Adverse Drug Reactions in Patients Undergoing Percutaneous Coronary Intervention. Circulation.
  • Vis forfatter(e) (2019). Patients’ Perceptions of Generic Drugs After Percutaneous Coronary Intervention: A Multicentre Cohort Study. Circulation.
  • Vis forfatter(e) (2017). Factors affecting in-hospital sleep-wake pattern in octogenarians during the early postoperative phase after transcutaneous aortic valve replacement. European Journal of Cardiovascular Nursing. 53.
  • Vis forfatter(e) (2016). Ultrasound and microbubble enhanced treatment of inoperable pancreatic adeonocarcinoma. Journal of Clinical Oncology.
  • Vis forfatter(e) (2015). The Drug Information Centre in 2015 – still a valid concept? Clinical Therapeutics. e168-e168.
  • Vis forfatter(e) (2013). Joint Medicines Information and Pharmacovigilance Services Could Improve Detection of New Drug Safety Information. Drug Safety. 910-910.
  • Vis forfatter(e) (2011). PREVALENCE OF PREGABALIN IN URINE SAMPLES FROM PATIENTS TREATED FOR SUBSTANCE-DEPENDENCY. Basic & Clinical Pharmacology & Toxicology. 79-79.
  • Vis forfatter(e) (2011). Gender Differences in Adverse Drug Reaction (ADR) Reporting in Children in Norway 2001-2010. Drug Safety. 979-979.
  • Vis forfatter(e) (2009). Ultra high field 7T MRI of the ex vivo perfused rat heart. Cardiology. 105-106.
  • Vis forfatter(e) (2009). Ten Years of Spontaneous Reporting of Adverse Drug Reactions in Children in Norway. Drug Safety. 924-924.
  • Vis forfatter(e) (2009). Drug use in pregnancy-are there differences between common sources of information? Pharmacy World & Science (PWS). 49-49.
  • Vis forfatter(e) (2008). Use of antibacterials and urinary tract prophylactic agents in Norwegian nursing homes. Pharmacoepidemiology and Drug Safety. S48-S49.
  • Vis forfatter(e) (2008). New methods to study complexity of drug information queries. Pharmacoepidemiology and Drug Safety. S50-S51.
  • Vis forfatter(e) (2008). Drug use in pregnancy - Service and clinical impact of drug information centres. Pharmacoepidemiology and Drug Safety. S157-S158.
  • Vis forfatter(e) (2007). Hepatitis caused by a natural product? Drug Safety. 944-944.
  • Vis forfatter(e) (2007). Drug use in pregnancy: Are there differences between common sources of information? Drug Safety. 954-954.
Poster
  • Vis forfatter(e) (2022). Which elements do we include, and how do we present them, in answers on use of medications during breastfeeding? A descriptive pilot study. .
  • Vis forfatter(e) (2022). Breastfeeding and treatment of nausea and vomiting during pregnancy – do we need updated guidelines? A review of questions to a medicines information service for pregnant and breastfeeding women .
  • Vis forfatter(e) (2021). Establishing an LC-MS/MS method as a tool in a TDM approach when treating multiple sclerosis with monoclonal antibodies.
  • Vis forfatter(e) (2019). role of intracellular cytidine deaminase activity for gemcitabine metabolism in pancreatic cancer cell lines.
  • Vis forfatter(e) (2019). Sonoporation and gemcitabine delivery in pancreatic cell lines.
  • Vis forfatter(e) (2019). Sonoporation and gemcitabine delivery in pancreatic cancer cell lines.
  • Vis forfatter(e) (2019). Intracellular cytidine deaminase and gemcitabine metabolism in three pancreatic cancer cell lines.
  • Vis forfatter(e) (2019). Intracellular cytidine deaminase and gemcitabine metabolism in three pancreatic cancer cell lines.
  • Vis forfatter(e) (2019). Experience with the internet-based service SafeMummyMedicine: A Norwegian medicines information service for pregnant and breastfeeding women.
  • Vis forfatter(e) (2018). Octogenarian patients’ experiences with hypnotics in relations to sleep disturbance and delirium after aortic valve replacement.
  • Vis forfatter(e) (2018). Liquid Chromatography Quadrupole Time of Flight Mass Spectrometry as a diagnostic tool in clinical toxicology.
  • Vis forfatter(e) (2016). Psychotropic Drug Exposure and Hip Fractures.
  • Vis forfatter(e) (2015). PHYSICIANS’ PERCEPTION OF TERATOGENIC RISK AND CONFIDENCE IN PRESCRIBING INFLUENCE OF NORWEGIAN MEDICINES INFORMATION CENTRES.
  • Vis forfatter(e) (2014). Stability of gemcitabine and metabolite in blood samples from pancreatic cancer patients.
  • Vis forfatter(e) (2013). CEDIA for buprenorfin, metadon og EDDP i urin- er det enkleste godt nok?
  • Vis forfatter(e) (2012). Hvilke spørsmål får RELIS om alternativ medisin – og hvordan svarer vi?
  • Vis forfatter(e) (2012). Diazoxide protects against doxorubicin-induced cardiotoxicity in the rat.
  • Vis forfatter(e) (2010). Prevention of urinary tract infections in Norwegian nursing homes.
  • Vis forfatter(e) (2010). Hypersensitivity Reactions to Drugs: A Retrospective Analysis of Clinical Characteristics of Patients Consulting for Suspected Drug Hypersensitivity in an Allergy Center in Norway.
  • Vis forfatter(e) (2010). Determination of hydrogen peroxide in isolated rat hearts.
  • Vis forfatter(e) (2009). 10 years of adverse drug reaction reporting among children.
  • Vis forfatter(e) (2008). Fabry disease: Unusual symptoms in two male children treated with lamotrigine and fabrazyme, respectively.
  • Vis forfatter(e) (2007). Drug use in pregnancy – are there differences between common sources of information?
  • Vis forfatter(e) (2003). A free web-based, full-text drug information database.
  • Vis forfatter(e) (2001). A web-based full-text drug information database (RELISWeb).
  • Vis forfatter(e) (2000). Is problem-oriented drug information a method to change clinical practice?
  • Vis forfatter(e) (1999). Polypharmacy among hospitalized patients with rheumatoid arthritis or polyarthritis.
  • Vis forfatter(e) (1998). Who needs a drug information centre? An evaluation.
  • Vis forfatter(e) (1998). Who needs a drug information centre? An evaluation.
Vitenskapelig oversiktsartikkel/review
  • Vis forfatter(e) (2022). Sykepleiere kan få pasienter med hjertesvikt til å ta medisinen. Tidsskriftet sykepleien.
  • Vis forfatter(e) (2020). Ultrakort om farmakogenetikk. Utposten. 42-43.
  • Vis forfatter(e) (2020). SafeMotherMedicine: Aiming to increase women’s empowerment in use of medications during pregnancy and breastfeeding. Maternal and Child Health Journal. 531-536.
  • Vis forfatter(e) (2020). Review of questions concerning clinical drug interactions in ADHD treatment from physicians in Norway. Frontiers in Pharmacology.
  • Vis forfatter(e) (2019). Norwegian drug information centres strongly promote person-centred and personalised medicine: a brief report on the achievements and strategy. EPMA Journal. 109-114.
  • Vis forfatter(e) (2019). Drug information centres and their provision of decision support: The Scandinavian experience. Journal of Clinical Pharmacy and Therapeutics. 489-492.
  • Vis forfatter(e) (2017). Ultrakort om biologiske legemidler. Norsk Farmaceutisk Tidsskrift. 24-25.
  • Vis forfatter(e) (2010). Håndtering av seponeringsreaksjoner. Tidsskrift for Den norske legeforening. 37-38.
  • Vis forfatter(e) (2009). Pregabalin og misbrukspotensial. Tidsskrift for Den norske legeforening. 186-187.
  • Vis forfatter(e) (2009). Hestekastanje-naturlegemiddel mot venøs insuffisiens. Tidsskrift for Den norske legeforening. 420-422.
  • Vis forfatter(e) (2008). Vareniklin (Champix)-nytt legemiddel for røykeavvenning. Tidsskrift for Den norske legeforening. 1962-1963.
  • Vis forfatter(e) (2008). Dosering av legemidler ved over-og undervekt. Tidsskrift for Den norske legeforening. 1843-1844.
  • Vis forfatter(e) (2006). Legemiddelinformasjonsmetoder for å påvirke legers praksis? Norsk Farmaceutisk Tidsskrift. 24-26.
  • Vis forfatter(e) (2004). Delivering balanced and quality drug information to professionals. International Pharmacy Journal. 19-20.
  • Vis forfatter(e) (2002). Reseptfritt-problemfritt for brukeren? Norsk Farmaceutisk Tidsskrift. 23-23.
  • Vis forfatter(e) (2001). Spørsmål og svar-nå på Internett: www.relis.no/database. Norsk Farmaceutisk Tidsskrift. 21-22.
  • Vis forfatter(e) (2000). Statiner og muskelbivirkninger. Tidsskrift for Den norske legeforening. 3729-3731.
  • Vis forfatter(e) (1996). Kryssreaksjoner mellom ACE-hemmere ved angioødem og eksfoliativ dermatitt? Tidsskrift for Den norske legeforening. 2348-2348.
Fagartikkel
  • Vis forfatter(e) (2022). Bytte legemidler – hva bør man tenke på? Utposten. 54-55.
  • Vis forfatter(e) (2015). Trygg Medisin - ny publikumstjeneste. Utposten. 56-56.
  • Vis forfatter(e) (2005). Imigran til sulfaallergiker. Utposten. 43-43.
  • Vis forfatter(e) (2001). RELIS spørsmål og svar-database på Internett. Utposten. 38-39.
  • Vis forfatter(e) (1999). Polyfarmasi hos en eldre pasient. Utposten. 36-38.
  • Vis forfatter(e) (1998). Zantac (ranitidin) og effekt på sæd. Utposten. 31-31.
  • Vis forfatter(e) (1997). Bivirkninger av Betolvex injeksjon? Utposten. 254-254.
  • Vis forfatter(e) (1996). Sopp og amming. Utposten. 284-285.
Faglig kapittel
  • Vis forfatter(e) (2018). Legemiddelinformasjon. 192-203. I:
    • Vis forfatter(e) (2018). Samfunnsfarmasi. Fagbokforlaget.

Se fullstendig oversikt over publikasjoner i CRIStin.